The interest from pharmaceutical giant GlaxoSmithKline in marketing and selling Satipharm CBD products has validated Cann Group’s decision to acquire the business and its work in registering an S3 over-the-counter medicine, its chief operating officer has said.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

Shane Duncan insisted the exclusive “evaluation and option” agreement with GSK Consumer Healthcare – soon to be renamed Haleon – has demonstrated why Cann Group purchased Satipharm from Canada-based Harvest One early last year.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...